Lupin Ltd share price today (on 1 October 2023).

We Provide Best stock tips for Lupin Ltd . A1 Intraday Tips is accurate share tips Provider Company in India in Nse market. A1 Intraday Tips, also provide Daily Charts with Nse Share Market current price of Lupin Ltd with today performance in nse market. Contact Us for Jackpot Stock tips.

Get Free Stock Tips for Lupin Ltd

Live Chart -

Lupin Ltd is an India-based pharmaceutical company. The company produces a range of generic and branded formulations and Active Pharmaceutical Ingredients (APIs). The company's product basket consists of formulations from Cephalosporins, CVS, CNS, Anti-Asthma, Anti-TB, Diabetology, Dermatology, GI, and other therapy segments. The company's drug delivery platforms include Bioadhesive/Gastroretentive Extended Release, Laser-Drilled Extended Release, Matrix/Coated Extended Release, Taste Masking Technologies and Improved Bioavailability through Solubilizationand Nano-particle technology. Their APIs products include antibiotics, Antibiotics, ANTI-TB, Cardiovasculars, Central Nervous System, Analegesics and ANTI-GOUT. Lupin Ltd was incorporated in the year 1983 with the name Lupin Chemicals Ltd. In the year 1987, the company commenced operations in Cephalexin Plant at Mandideep and 7 ADCA plant at Ankleshwar. In the year 1989, the company established a joint venture in Thailand, namely Lupin Chemicals (Thailand) Ltd. In the year 1991, they initiated production of Injectable cephalosporin (bulk and dosages) at Mandideep.
Lupin commenced business in the year 1968, has successfully positioned itself as a Transnational Pharmaceutical Company, with a wide global footprint. The Company develops and markets a wide range of quality, affordable generic and branded formulations and APIs for the developed and developing markets of the world. Lupin first gained recognition when it became one of the world's largest manufacturers of Tuberculosis drugs.
In the year 1992, the company set up Fermentation Plant at Tarapur, Maharashtra. Also, Sterile Plant for injectable Cephalosporins (bulk) was commissioned at Mandideep. In the year 2001, Lupin Laboratories Ltd was amalgamated with the company and the name was changed to Lupin Ltd. They commenced supply of Cephalosporin bulk actives to their alliance partners in the US. Also, they commissioned a state of the art US FDA approvable oral cephalosporin bulk active plant. In the year 2002, the company commissioned the new Anti-TB facility at Aurangabad. In the year 2003, they formed Lupin Pharmaceuticals Inc. USA, for trading, marketing and developmental activities in the US. In the year 2006, the company set up a new facility at Jammu. In the year 2007, the company acquired Vadodara based Rubamin Laboratories Ltd (rechristened to Novodigm Ltd). Also, they acquired Kyowa Pharmaceutical Industry Company Limited, a leading Generic Company in Japan. They started commercial production at their newly finished dosage facility at Jammu. Also, they set a new finished dosage facility at Indore. During the year 2008-09, the company expanded their product basket in Japan-Kyowa and received ten products approval from Ministry of Health & Labour Welfare, Japan. They acquired 100% stake in Hormosan Pharma GmbH, a generic company in Germany. Also, they acquired 36.65% stake in Generic Health Pty Ltd., in Australia, 60% stake in Pharma Dynamics in South Africa and 51% stake in Multicare Pharmaceuticals Philippines Inc in Philippines. During the year 2009-10, Lupin (Europe) Ltd, UK and Lupin Pharma Canada Ltd, Canada were incorporated on June 5, 2009 and June 18, 2009 respectively. Lupin Holding B V, the Netherlands transferred their holdings in Max Pharma Pty Ltd, Australia, a wholly owned subsidiary of the company to Generic Healthy Pty Ltd, Australia, an associated of the company upon which Max Pharma Pty Ltd ceased to be a subsidiary of the company with effect from May 31, 2009.
In January 2010, as per the scheme of amalgamation, Novodigm Ltd, Lupin Pharmacare Ltd and Lupin Herbal Ltd, wholly owned subsidiaries of the company were amalgamated with the company with effect from April 1, 2009. In August 23, 2010, the company incorporated Lupin Mexico SA de CV, Mexico as a subsidiary company. The company increased their stake in Generic Health Pty Ltd., (Generic), Australia, from 49.91% to 76.65% and thus Generic became a subsidiary of the company with effect from September 27, 2010. Consequently, Bellwether Pharma Pty Ltd., Australia, Generic Health Inc., U.S.A. and Max Pharma Pty Ltd., Australia, which were subsidiaries of Generic, became subsidiaries of the company with effect from September 27, 2010. The company incorporated Lupin Philippines, Inc., Philippines and Lupin Healthcare Ltd., India, as subsidiaries on December 20, 2010 and March 17, 2011 respectively. In June 2011, the company's Generic Healthy Pty Ltd acquired worldwide rights for the Goanna Brand and the complete range of premium therapeutic oils, rubs and ointments marketed under the brand. In July 2011, the company entered into a research and development agreement with Medicis Pharmaceutical Corporation (Medicis) to apply Lupin technologies to multiple therapeutic compounds. In November 2011, the company acquired I'rom Pharmaceuticals through their Japanese subsidiary.
According to the Consolidated - Audited financial statement for the Year of 2012, total net operating revenues increased with 17.91%, from INR 5,750.21 tens of millions to INR 6,780.35 tens of millions. Operating result increased from INR 1,155.37 tens of millions to INR 1,429.26 tens of millions which means 23.71% change. The results of the period increased 0.90% reaching INR 886.95 tens of millions at the end of the period against INR 879.07 tens of millions last year. Return on equity (Net income/Total equity) went from 26.47% to 21.88%, the Return On Asset (Net income / Total Asset) went from 15.26% to 12.54% and the Net Profit Margin (Net Income/Net Sales) went from 15.29% to 13.08% when compared to the same period of last year. The Debt to Equity Ratio (Total Liabilities/Equity) was 96.75% compared to 86.39% of last year.

Nse Listed Companies with Live Charts